Zacks Investment Research lowered shares of CRH Medical (NYSEAMERICAN:CRHM) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.
According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “
A number of other equities analysts have also weighed in on CRHM. TD Securities raised shares of CRH Medical from a hold rating to a buy rating in a research note on Friday, July 27th. TheStreet raised shares of CRH Medical from a c rating to a b- rating in a research note on Friday, August 24th.
Shares of NYSEAMERICAN CRHM opened at $3.25 on Tuesday. CRH Medical has a 1-year low of $1.46 and a 1-year high of $4.50.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ClariVest Asset Management LLC acquired a new position in shares of CRH Medical during the 3rd quarter worth about $154,000. Acadian Asset Management LLC acquired a new stake in CRH Medical in the 3rd quarter valued at about $354,000. Wedge Capital Management L L P NC acquired a new stake in CRH Medical in the 3rd quarter valued at about $373,000. Renaissance Technologies LLC lifted its stake in CRH Medical by 46.0% in the 2nd quarter. Renaissance Technologies LLC now owns 383,600 shares of the company’s stock valued at $1,189,000 after purchasing an additional 120,800 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in CRH Medical by 21.9% in the 1st quarter. JPMorgan Chase & Co. now owns 899,700 shares of the company’s stock valued at $2,294,000 after purchasing an additional 161,800 shares during the last quarter.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
Read More: NASDAQ Stock Market Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.